The Factors Influencing the Success of Redo Surgery and Anal Function for Anastomosis Failure or Local Tumor Recurrence

February 25, 2026 updated by: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

A Multicenter Retrospective Study in China: the Factors Influencing the Success of Redo Surgery and Anal Function for Anastomosis Failure or Local Tumor Recurrence

To analyze the influencing factors of the success of redo surgery due to anastomotic fistula or anastomotic recurrence after rectal cancer surgery and to evaluate the anal function of patients

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Redo surgery is a critical salvage strategy for anastomotic complications or local recurrence following rectal cancer resection. Despite technical feasibility, functional outcomes remain suboptimal. This study evaluated intestinal continuity restoration and anal function recovery after redo surgery, alongside prognostic factors influencing outcomes. A retrospective multicenter study analyzed 143 patients undergoing redo surgery (2015-2023) for anastomotic failure or local recurrence. Primary endpoints included anatomical restoration of intestinal continuity, while secondary endpoints assessed functional outcomes using the LARS score.

Study Type

Observational

Enrollment (Actual)

143

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

This retrospective, multicenter study analyzed data from a prospectively maintained redo surgery registry spanning March 2015 to March 2023. Patients were recruited from Cancer Hospital Chinese Academy of Medical Sciences,Sun Yat-sen University Sixth Affiliated Hospital and Yifu Hospital Affiliated to Nanjing Medical University.

Description

Inclusion Criteria:

  • Prior curative resection for primary colorectal adenocarcinoma.
  • Subsequent reoperation for anastomotic failure or locoregional recurrence.
  • Absence of absolute contraindications to reoperative surgery.

Exclusion Criteria:

  • Primary tumors located proximal to the sigmoid colon.
  • Radiologically confirmed distant metastases.
  • Presence of a permanent stoma at the time of questionnaire administration.
  • Insufficient literacy or cognitive function to complete study-related -questionnaires.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Whether postoperative patients with rectal cancer can restore intestinal continuity, that is, defecate through the anus
Time Frame: During the follow-up period, at least two years after rectal cancer surgery
During the follow-up period, at least two years after rectal cancer surgery

Secondary Outcome Measures

Outcome Measure
Time Frame
Low Anterior Rectal Syndrome (LARS) Score of patients restoring intestinal continuity
Time Frame: During the follow-up period, at least one year has passed since the intestinal continuity was restored
During the follow-up period, at least one year has passed since the intestinal continuity was restored

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2006

Primary Completion (Actual)

March 1, 2023

Study Completion (Actual)

December 31, 2023

Study Registration Dates

First Submitted

September 3, 2025

First Submitted That Met QC Criteria

February 25, 2026

First Posted (Actual)

February 27, 2026

Study Record Updates

Last Update Posted (Actual)

February 27, 2026

Last Update Submitted That Met QC Criteria

February 25, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NCC25721

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Colo-rectal Cancer

Clinical Trials on redo surgery

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Papua New Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe